Pharma BD Deal Intelligence
Ethicon (a J&J subsidiary) agreed to acquire Auris Health for approximately $3.4B in cash plus up to $2.35B in contingent milestone payments. Auris's lead platform was the FDA-cleared Monarch robotic bronchoscopy system for lung cancer diagnosis. Acquisition closed April 1, 2019. Post-close, the up-to-$2.35B contingent earnout became the subject of major litigation: in J&J v. Fortis Advisors (Delaware), a Sept 2024 Chancery judgment awarded former Auris shareholders more than $1B, finding J&J committed fraud and breached commercially-reasonable-efforts obligations on the milestone payments; the Delaware Supreme Court (Jan 2026) affirmed the fraud finding and breach on most milestones while reversing the Milestone 1 (lung ablation 510(k)) damages and remanding for interest recalculation. The Monarch platform itself advanced under J&J with FDA 510(k) clearance of the AI-enabled MONARCH QUEST in March 2025 and publication of the 679-patient TARGET study in CHEST in May 2025.
Assessment window: 5yr post-close.